Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection. What will really matter in the long run? That’s the question we tackle each year as ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

A NEW injection that could prevent HIV infection has successfully completed an early safety trial, according to a report in ...

However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...

The cancellation of USAID contracts has threatened critical global health research. Plus, new guidance to prevent HIV in ...

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Mexican health authorities reported 22 cases of measles on Thursday, following an outbreak in the United States where it has ...